Loading...
Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer
The loss-of-function mutation of formyl peptide receptor 1 (FPR1) has a negative impact on the progression-free and overall survival of breast cancer patients treated with anthracycline-based adjuvant chemotherapy. This effect may be attributed to the fact that chemotherapy-induced antitumor immunit...
Na minha lista:
| Udgivet i: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4938360/ https://ncbi.nlm.nih.gov/pubmed/27471610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1139275 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|